根据美国证券交易委员会（SEC）最新提交的文件显示，Matinas BioPharma Holdings, Inc（以下简称“Matinas BioPharma”）在终止其销售协议的过程中，并未产生任何解约罚款或相关费用。这一消息意味着，该公司在终止合作时无需承担额外的财务负担，避免了潜在的财务损失。
根据美国证券交易委员会（SEC）最新提交的文件显示，Matinas BioPharma Holdings, Inc（以下简称“Matinas BioPharma”）在终止其销售协议的过程中，并未产生任何解约罚款或相关费用。这一消息意味着，该公司在终止合作时无需承担额外的财务负担，避免了潜在的财务损失。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.